2025 Goals
Thanks to the funding secured in 2024, the focus shifts to recruiting and training a strong business development team. With a dedicated sales organization, we expect to move faster on revenue growth. In 2024, we successfully entered new markets and progressed key agreements; in 2025, the goal is to finalize those deals and consolidate our presence.
Revenue
| Metric | Target | Baseline (2024) |
|---|---|---|
| Revenue | €1,437,755 | €410,787 |
| Growth | 3.5x (250%) | — |
Market Expansion
Target: 2 new markets
Priority regions: Markets with regulatory alignment and strong private healthcare sectors.
Regulatory Certification
| Certification | Market | Status |
|---|---|---|
| FDA 510(k) | United States | Planned |
| ANVISA | Brazil | Planned |
Customer Success
| Metric | Target | Frequency |
|---|---|---|
| CSAT | >75% | Quarterly + end of each clinical study |
| CUS | >70% | Bi-annually + end of each clinical study |
Focus: Establish systematic measurement cadence for customer satisfaction and clinical utility scores.